Samsung Unit Sues To Invalidate Novartis Syringe Patents
Samsung's biotech business urged a London court to invalidate five of rival Novartis AG's patents related to syringe technology because they are "uninventive."...To view the full article, register now.
Already a subscriber? Click here to view full article